Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Kesselheim

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Transactions & Studies of the College of Physicians of Philadelphia|June 29, 2002
Deception and presidential disability: an historical analysisA S Kesselheim
Clinical Pharmacology and Therapeutics|July 21, 2012
Ethical considerations in orphan drug approval and useA S Kesselheim
Clinical Pharmacology and Therapeutics|May 20, 2009
Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug developmentA S Kesselheim
Clinical Pharmacology and Therapeutics|May 21, 2010
Permitting product liability litigation for FDA-approved drugs and devices promotes patient safetyA S Kesselheim
Clinical Pharmacology and Therapeutics|August 13, 2015
The 21st century cures act: Opportunities and challengesA Sarpatwari, A S Kesselheim
Clinical Pharmacology and Therapeutics|January 23, 2014
The evolving role of biomarker patents in personalized medicineA S Kesselheim, N Shiu
Clinical Pharmacology and Therapeutics|October 18, 2012
Drug labels: a flawed source of data for studying orphan drug approvalsA S Kesselheim, J Avorn
Clinical Pharmacology and Therapeutics|June 24, 2017
Challenges in the Development of Novel Cardiovascular TherapiesT J Hwang, A S Kesselheim
Clinical Pharmacology and Therapeutics|November 7, 2013
Strategies for postmarketing surveillance of drugs for rare diseasesA S Kesselheim, J J Gagne
Clinical Pharmacology and Therapeutics|February 12, 2015
FDA designations for therapeutics and their impact on drug development and regulatory review outcomesA S Kesselheim, J J Darrow
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Transactions & Studies of the College of Physicians of Philadelphia|June 29, 2002
Deception and presidential disability: an historical analysisA S Kesselheim
Clinical Pharmacology and Therapeutics|July 21, 2012
Ethical considerations in orphan drug approval and useA S Kesselheim
Clinical Pharmacology and Therapeutics|May 20, 2009
Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug developmentA S Kesselheim
Clinical Pharmacology and Therapeutics|May 21, 2010
Permitting product liability litigation for FDA-approved drugs and devices promotes patient safetyA S Kesselheim
Clinical Pharmacology and Therapeutics|August 13, 2015
The 21st century cures act: Opportunities and challengesA Sarpatwari, A S Kesselheim
Clinical Pharmacology and Therapeutics|January 23, 2014
The evolving role of biomarker patents in personalized medicineA S Kesselheim, N Shiu
Clinical Pharmacology and Therapeutics|October 18, 2012
Drug labels: a flawed source of data for studying orphan drug approvalsA S Kesselheim, J Avorn
Clinical Pharmacology and Therapeutics|June 24, 2017
Challenges in the Development of Novel Cardiovascular TherapiesT J Hwang, A S Kesselheim
Clinical Pharmacology and Therapeutics|November 7, 2013
Strategies for postmarketing surveillance of drugs for rare diseasesA S Kesselheim, J J Gagne
Clinical Pharmacology and Therapeutics|February 12, 2015
FDA designations for therapeutics and their impact on drug development and regulatory review outcomesA S Kesselheim, J J Darrow
Pageof 2